StockData
Xeris Biopharma Holdings, Inc. logo

Xeris Biopharma Holdings, Inc. (XERS) stock

XERSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30
$16.99+0.19 (+1.13%)

Close on Nov 18, 2026Market cap $3.10BP/E –Yield –

Xeris Biopharma price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Xeris Biopharma's price to book ratio was 107.2× on Jul 31, 2026, against 11.9× a year earlier. Over the last 3 years it ranged from 1.4× to 107.2×, with a median of 6.8×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Jul 31, 2026107.2×+19.3
2024Jan 31, 202487.9×+3.9
2023Dec 29, 202383.9×+80.7
2022Dec 30, 20223.3×+0.0
2021Oct 29, 20213.3×–

More Xeris Biopharma figures

See a number that looks wrong?